PRTN3 and autoimmune disease: Notably, pharmaceutical inhibition of cathepsin C has also been shown to suppress NE and PR3 activity in models of vasculitis, resulting in reduced NET burden and decreased disease severity in MPO-ANCA-associated vasculitis (MPO-AAV), a neutrophil-driven autoimmune disorder [16].